🎯 check ASP2215 (Gilteritinib) product page
Gilteritinib is a potent, ATP-competitive FLT3/AXL/ALK inhibitor. It blocks AKT/ERK/STAT5 signaling by binding to the active kinase conformation, effectively inhibiting proliferation and inducing apoptosis in mutated AML and ALK-rearranged cancers.